Short, all-Oral Regimens for Rifampicin-resistant Tuberculosis (ShORRT)
Latest Information Update: 25 Jun 2024
At a glance
- Drugs Bedaquiline (Primary) ; Linezolid (Primary)
- Indications Tuberculosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms ShORRT
Most Recent Events
- 03 Feb 2023 New trial record
- 31 Jan 2023 The trial is expected to end on 21-Jun-2024, according to ISRCTN: Current Controlled Trials.